Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mitsuhiro Watanabe, Sander M. Houten, Li Wang, Antonio Moschetta, David J. Mangelsdorf, Richard A. Heyman, David D. Moore, Johan Auwerx
Published in Volume 113, Issue 10
J Clin Invest. 2004; 113(10):1408–1418 doi:10.1172/JCI21025
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

LXR is essential for SHP-mediated lowering of TGs. (A) Serum TGs in wild-type and LXRα/β_/_ mice after treatment with 0.5% CA (age 10_14 weeks, n = 6). (B) Hepatic expression levels of SREBP-1c, CYP7A1, ME, and SHP in wild-type and LXRα/β_/_ mice after treatment with CA as determined using quantitative RT-PCR. # denotes P = 0.09 (n = 6). (C) A FXR-SHP-SREBP-1c regulatory cascade. Schematic representation of the proposed role of SHP in mediating the effects of FXR agonists on SREBP-1c expression and lipogenesis.